医学
阿替唑单抗
药代动力学
危险系数
不利影响
置信区间
临床终点
临床研究阶段
生物等效性
泌尿科
外科
内科学
胃肠病学
临床试验
癌症
免疫疗法
彭布罗利珠单抗
作者
Mauricio Burotto,Zanete Zvirbule,A. Mochalova,Yotsawaj Runglodvatana,Luis A. Herráez-Baranda,Sinan Liu,Phyllis Chan,E. Shearer-Kang,Xiaoyan Liu,Nadia Tosti,J.A. Zanghi,B. Leutgeb,Enriqueta Felip
标识
DOI:10.1016/j.annonc.2023.05.009
摘要
Atezolizumab intravenous (IV) is approved for the treatment of various solid tumours. To improve treatment convenience and health care efficiencies, a coformulation of atezolizumab and recombinant human hyaluronidase PH20 was developed for subcutaneous (SC) use. Part 2 of IMscin001 (NCT03735121) was a randomised phase III, open-label, multicentre, noninferiority study comparing the drug exposure of atezolizumab SC with atezolizumab IV.
科研通智能强力驱动
Strongly Powered by AbleSci AI